Ampio Pharmaceuticals (AMPE) Competitors $0.0021 0.00 (0.00%) As of 04/17/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock AMPE vs. CMRA, GNCAQ, GNCA, ARDS, CALA, STAB, EFTR, ONCSQ, PXMD, and ATNFWShould you be buying Ampio Pharmaceuticals stock or one of its competitors? The main competitors of Ampio Pharmaceuticals include Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Calithera Biosciences (CALA), Statera Biopharma (STAB), eFFECTOR Therapeutics (EFTR), OncoSec Medical (ONCSQ), PaxMedica (PXMD), and 180 Life Sciences (ATNFW). These companies are all part of the "pharmaceutical products" industry. Ampio Pharmaceuticals vs. Comera Life Sciences Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Calithera Biosciences Statera Biopharma eFFECTOR Therapeutics OncoSec Medical PaxMedica 180 Life Sciences Ampio Pharmaceuticals (NYSE:AMPE) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, community ranking, earnings, profitability and media sentiment. Which has more risk and volatility, AMPE or CMRA? Ampio Pharmaceuticals has a beta of 3.73, indicating that its share price is 273% more volatile than the S&P 500. Comparatively, Comera Life Sciences has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Do institutionals and insiders hold more shares of AMPE or CMRA? 5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. 3.3% of Ampio Pharmaceuticals shares are owned by insiders. Comparatively, 8.9% of Comera Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is AMPE or CMRA more profitable? Company Net Margins Return on Equity Return on Assets Ampio PharmaceuticalsN/A N/A N/A Comera Life Sciences N/A N/A N/A Does the media favor AMPE or CMRA? In the previous week, Ampio Pharmaceuticals had 1 more articles in the media than Comera Life Sciences. MarketBeat recorded 1 mentions for Ampio Pharmaceuticals and 0 mentions for Comera Life Sciences. Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score. Company Overall Sentiment Ampio Pharmaceuticals Neutral Comera Life Sciences Neutral Which has preferable earnings and valuation, AMPE or CMRA? Ampio Pharmaceuticals has higher earnings, but lower revenue than Comera Life Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmpio PharmaceuticalsN/AN/A-$8.63M-$11.010.00Comera Life Sciences$1.00M0.01-$18MN/AN/A Does the MarketBeat Community prefer AMPE or CMRA? Ampio Pharmaceuticals and Comera Life Sciences both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformAmpio PharmaceuticalsOutperform VotesNo VotesUnderperform Votes74100.00% Comera Life SciencesN/AN/A SummaryAmpio Pharmaceuticals beats Comera Life Sciences on 4 of the 6 factors compared between the two stocks. Get Ampio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMPE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart AMPE vs. The Competition Export to ExcelMetricAmpio PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$2,000.00$6.46B$5.32B$18.42BDividend YieldN/A3.21%5.47%4.17%P/E Ratio0.006.9521.9431.09Price / SalesN/A231.01380.9426.53Price / CashN/A65.6738.3117.52Price / Book0.005.936.454.30Net Income-$8.63M$143.22M$3.22B$1.02B7 Day PerformanceN/A4.28%5.85%1.42%1 Month PerformanceN/A-13.11%-9.58%-7.92%1 Year PerformanceN/A-8.51%11.85%1.71% Ampio Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMPEAmpio PharmaceuticalsN/A$0.00flatN/A-99.6%$2,000.00N/A0.0020Analyst ForecastNews CoverageCMRAComera Life SciencesN/A$0.00flatN/AN/A$6,000.00$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6,000.00N/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070Analyst ForecastNews CoverageARDSAridis PharmaceuticalsN/A$0.00flatN/AN/A$5,000.00$3.09M0.0030CALACalithera BiosciencesN/A$0.00flatN/A-80.0%$5,000.00N/A0.0060Analyst ForecastNews CoverageGap DownSTABStatera BiopharmaN/A$0.00flatN/A-85.7%$5,000.00N/A0.0020EFTReFFECTOR TherapeuticsN/A$0.00flatN/A-100.0%$1,000.00$3.55M0.0010ONCSQOncoSec MedicalN/AN/AN/AN/A$1,000.00N/A0.0040PXMDPaxMedicaN/A$0.00-50.0%N/A-100.0%$1,000.00N/A0.002Gap DownHigh Trading VolumeATNFW180 Life SciencesN/A$0.01-2.5%N/A-12.2%$0.00N/A0.007Positive NewsGap Down Related Companies and Tools Related Companies Comera Life Sciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Aridis Pharmaceuticals Competitors Calithera Biosciences Competitors Statera Biopharma Competitors eFFECTOR Therapeutics Competitors OncoSec Medical Competitors PaxMedica Competitors 180 Life Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:AMPE) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredTrump’s Top Secret $9 Trillion AI SuperweaponJeff Brown spotted Nvidia at $1. Now he’s revealing a new AI superweapon — and the Musk-connected stocks that ...Brownstone Research | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ampio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ampio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AMPE Stock Free AMPE Stock Alerts